XSHE
300026
Market cap1.45bUSD
Oct 09, Last price
3.32CNY
1D
2.79%
1Q
4.73%
Jan 2017
-38.86%
IPO
57.82%
Name
Tianjin Chase Sun Pharmaceutical Co Ltd
Chart & performance
P/E
539.27
P/S
2.03
EPS
0.01
Div yield, %
0.93%
Shrs. gr., 5y
0.11%
Rev. gr., 5y
-8.57%
Revenues
4.90b
-15.23%
Net income
18m
-13.85%
CFO
811m
-4.80%
Dividend
Jul 15, 20260.01 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves the fields of immunity, cardiovascular and cerebrovascular diseases, respiratory system, and neurodegenerative diseases. The company was founded in 1996 and is headquartered in Tianjin, China.
Key people
Wenyuan Wu
Chairman of the Board · since 2024
Wujun Lan
Vice Chairman of the Board, General Manager · since 2024
Ruiqiang Chen
Deputy General Manager · since 2015
Xiaozhong Lu
Deputy General Manager · since 2023
Wu Sun
Finance Director, Executive Deputy General Manager, Director · since 2024
Kun Zhang
Deputy General Manager · since 2019
Xing Jin
Senior Executive Officer · since 2026
Jiaping Dan
Director · since 2025
Chunxu Li
Deputy General Manager, Director · since 2024
Sen Lin
Director · since 2024
Yi Yang
Secretary of the Board, Director · since 2025
Ying Zhang
Director · since 2025
Independent Director · since 2020
Independent Director · since 2020
Independent Director · since 2020
Independent Director · since 2025
Headquarters & legal address
天津新技术产业园区武清开发区泉发路西
西青区, TJ 100000
CN
西青区, TJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||